A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00051760" target="_blank" >RIV/00216224:14110/10:00051760 - isvavai.cz</a>
Alternative codes found
RIV/00209805:_____/10:#0000272
Result on the web
<a href="http://dx.doi.org/10.1038/sj.bjc.6605872" target="_blank" >http://dx.doi.org/10.1038/sj.bjc.6605872</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/sj.bjc.6605872" target="_blank" >10.1038/sj.bjc.6605872</a>
Alternative languages
Result language
angličtina
Original language name
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
Original language description
Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb against IL-6, was evaluated in a three-part phase I/II study in patients with progressive metastatic RCC. METHODS: In part 1, 11 patients received 1, 3, 6, or 12 mg kg(-1) at weeks 1, 4 and q2w x 2 thereafter; in part 2, 37 patients randomly received 3 or 6 mg kg(-1) q3w x 4; in part 3, 20 low-risk patients received 6 mg kg(-1) q2w x 6. Modified WHO response criteria were assessed at weeks 7, 11, the 6-week follow-up, and when clinically indicated. RESULTS: Siltuximab was well tolerated overall, with no maximum tolerated dose or immune response observed. In all, 5 out of 11, 17 out of 37, and 9 out of 20 patients in parts 1, 2, and 3, respectively, received extended treatment beyond 4-6 initial infusions.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British journal of cancer
ISSN
0007-0920
e-ISSN
—
Volume of the periodical
103
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
1154-1162
UT code for WoS article
000283542900004
EID of the result in the Scopus database
—